GE HealthCare Technologies’ (NASDAQ: GEHC) MIM Software recently announced the receipt of FDA clearance for performing Centiloid scaling for positron emission tomography (PET)-based amyloid imaging analysis and quantification. With MIMneuro, a vendor-neutral solution, this new Centiloid scale tool is likely to be able to assist physicians in more accurately determining the density of amyloid plaque in a patient’s brain. Amyloid PET radiotracers help visualize amyloid plaque density in patients being evaluated for Alzheimer’s disease. Likely Trend of GEHC Stock Following the NewsFollowing the a…